Relapsed childhood acute lymphoblastic leukemia in the Nordic countries : prognostic factors, treatment and outcome

Show full item record



Permalink

http://hdl.handle.net/10138/161950

Citation

Oskarsson , T , Soderhall , S , Arvidson , J , Forestier , E , Montgomery , S , Bottai , M , Lausen , B , Carlsen , N , Hellebostad , M , Lahteenmaki , P , Saarinen-Pihkala , U M , Jonsson , O G , Heyman , M & Nordic Soc Paediat Haematology 2016 , ' Relapsed childhood acute lymphoblastic leukemia in the Nordic countries : prognostic factors, treatment and outcome ' , Haematologica , vol. 101 , no. 1 , pp. 68-76 . https://doi.org/10.3324/haematol.2015.131680

Title: Relapsed childhood acute lymphoblastic leukemia in the Nordic countries : prognostic factors, treatment and outcome
Author: Oskarsson, Trausti; Soderhall, Stefan; Arvidson, Johan; Forestier, Erik; Montgomery, Scott; Bottai, Matteo; Lausen, Birgitte; Carlsen, Niels; Hellebostad, Marit; Lahteenmaki, Paivi; Saarinen-Pihkala, Ulla M.; Jonsson, Olafur G.; Heyman, Mats; Nordic Soc Paediat Haematology
Contributor: University of Helsinki, Children's Hospital
Date: 2016-01
Language: eng
Number of pages: 9
Belongs to series: Haematologica
ISSN: 0390-6078
URI: http://hdl.handle.net/10138/161950
Abstract: Relapse is the main reason for treatment failure in childhood acute lymphoblastic leukemia. Despite improvements in the up-front therapy, survival after relapse is still relatively poor, especially for high-risk relapses. The aims of this study were to assess outcomes following acute lymphoblastic leukemia relapse after common initial Nordic Society of Paediatric Haematology and Oncology protocol treatment; to validate currently used risk stratifications, and identify additional prognostic factors for overall survival. Altogether, 516 of 2735 patients (18.9%) relapsed between 1992 and 2011 and were included in the study. There were no statistically significant differences in outcome between the up-front protocols or between the relapse protocols used, but an improvement over time was observed. The 5-year overall survival for patients relapsing in the period 2002-2011 was 57.5 +/- 3.4%, but 44.7 +/- 3.2% (P
Subject: MINIMAL RESIDUAL DISEASE
CHILDRENS ONCOLOGY GROUP
STEM-CELL TRANSPLANTATION
BFM STUDY-GROUP
DOWN-SYNDROME
1ST RELAPSE
PREDICTIVE FACTOR
MARROW RELAPSE
RISK
TRIAL
3123 Gynaecology and paediatrics
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1010068.pdf 1.307Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record